Loading…
Explore Solvonis Therapeutics' strategic rebrand, Awakn acquisition, and 2024 financial results as the UK biotech targets mental health innovation amid clinical trial risks and funding needs.
This article covers information on Solvonis Therapeutics PLC.
LON:SVNSIf corporate transformations were Olympic events, Solvonis Therapeutics would be eyeing a podium finish. The former Graft Polymer has shed its polymer skin entirely, emerging as a clinical-stage biotech targeting one of healthcare’s most urgent challenges: mental health and addiction treatment. Let’s dissect their 2024 results and strategic moves.
January’s shareholder-approved rebrand to Solvonis Therapeutics wasn’t just cosmetic surgery. This was a full organ transplant:
The numbers tell a story of radical focus – administrative expenses slashed by 32% to £1.47m, while R&D intensity rockets.
Solvonis’ pending acquisition of Awakn Life Sciences isn’t just another M&A line item. This £300k upfront deal (with potential earnouts) positions the group at the bleeding edge of:
But here’s the rub: Awakn itself is pre-revenue, carrying £2.09m in intangible assets that auditors note have “inherent uncertainty” around commercial viability.
Solvonis’ balance sheet reveals a biotech ballet between survival and ambition:
Related
Polar Capital Technology Trust sees 102% NAV growth in FY2026, beating its benchmark by 47 points thanks to AI and semiconductor exposure.
JoshuaJuly 10, 2026
Last updated
Category
InvestingViews
65 viewsLikes
No ratings yet
| Metric | 2024 | 2023 | Delta |
|---|---|---|---|
| Cash & Equivalents | £757k | £155k | +388% |
| Operating Loss | £1.38m | £3.12m | -56% |
| Net Assets | £3.08m | £2.03m | +52% |
The £1.59m comprehensive loss masks critical context: R&D spend now constitutes 72% of opex versus 41% in polymer days. This isn’t austerity – it’s targeted spending.
With £757k cash and monthly burn at ~£95k, Solvonis has an 8-month runway. The material uncertainty around going concern isn’t alarmist – it’s arithmetic. The proposed Awakn deal’s success hinges on concurrent fundraising that remains unsigned as of reporting.
Kreston Reeves’ audit flags four critical vulnerabilities:
Notably, the audit flags “substantial headroom” in sales models for existing partnerships – a rare positive in pre-revenue biotech assessments.
Solvonis’ trajectory hinges on three H2 2025 catalysts:
Investors should monitor:
Solvonis isn’t for the faint-hearted. With 307.6m warrants outstanding at 0.2p average strike, the capital structure resembles a biotech options play. Yet in a mental health crisis costing the UK economy £118bn annually, their pivot addresses a market where demand vastly outstrips supply.
As CEO Tennyson steers this ship into uncharted waters, one truth remains: in biotech, today’s cash burn fuels tomorrow’s breakthroughs. Solvonis has lit the fuse – now we wait for the bang.
Impax Q3 AUM rises to £23.3bn despite £1.7bn net outflows, driven by market gains and strong investment performance.
JoshuaJuly 10, 2026
MJ Gleeson FY2026 trading update: steady profits, mixed home sales with operational restructuring improving outlook.
JoshuaJuly 10, 2026
No comments yet - start the conversation.